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Background: Statins have several effects beyond their well-known antihyperlipidemic activity, which include
immunomodulatory, antioxidative and anticoagulant effects. In this study, we have tested the possible antimicrobial
activity of statins against a range of standard bacterial strains and bacterial clinical isolates.
Methods: Minimum inhibitory concentrations (MIC) values were evaluated and compared among three members
of the statins drug (atorvastatin, simvastatin, and rosuvastatin).
Results: It was revealed that statins are able to induce variable degrees of antibacterial activity with atorvastatin,
and simvastatin being the more potent than rosuvastatin. Methicillin-sensitive staphylococcus aureus (MSSA),
methicillin-resistant staphylococcus aureus (MRSA), vancomycin-susceptible enterococci (VSE), vancomycin-resistant
enterococcus (VRE), acinetobacter baumannii, staphylococcus epidermidis, and enterobacter aerogenes, were more
sensitive to both atorvastatin, and simvastatin compared to rosuvastatin. On the other hand, escherichia coli, proteus
mirabilis, and enterobacter cloacae were more sensitive to atorvastatin compared to both simvastatin and
rosuvastatin. Furthermore, most clinical isolates were less sensitive to statins compared to their corresponding
standard strains.
Conclusion: Our findings might raise the possibility of a potentially important antibacterial class effect for statins
especially, atorvastatin and simvastatin.
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Statins, also known as 3-hydroxy-3-methyl-glutaryl
(HMG)-CoA reductase inhibitors, are a potent antihy-
perlipidemic drug group that is widely used for the treat-
ment of hyperlipidemia. The HMG-CoA reductase is the
enzyme responsible for the rate-limiting step in the chol-
esterol synthesis mevalonate pathway [1]. HMG-CoA in-
hibition results in a reduction of cholesterol synthesis
and an increase in the synthesis of low-density-
lipoprotein receptors. This, results in increased clearance
of LDL cholesterol from the blood stream [2].
HMG-CoA reductase inhibitors are known to have
effects beyond their lipid lowering effects, collectively* Correspondence: mmmasadeh@just.edu.jo
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reproduction in any medium, provided the orknown as pleiotropic effects [3]. These pleiotropic effects
result in improvement of endothelial function, modula-
tion of inflammatory responses and antioxidant effects,
maintenance of plaque stability, and prevention of
thrombus formation [4-6]. The area of pleiotropic effects
of statins is promising and several such effects are being
speculated.
Statins have also been investigated for their antibacterial
action. In one study of the role of statins in community
acquired pneumonia, [7] statins were shown to have
immunomodulatory, and antioxidative actions, and a sig-
nificant effect on the concentrations systemic cytokine [8-
12]. Several animal studies [9,13-17] and observational
studies in humans [18-22] have shown that individuals
treated with statins are less prone to bacterial infection
and present better outcomes. The antibacterial and anti-
inflammatory effects of statins were investigated in aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with useful outcomes in the treatment and pre-
vention of different infections in recipients of solid-organ
transplants [23,24]. This study aims to further investigate
the antibacterial action of statins and identify their
spectrum of action.Table 1 Minimum inhibitory concentrations (MIC; μg/mL)
of different statins against standard bacteria
Statins Rosuvastatin Atorvastatin Simvastatin
MIC; μg/mL MIC; μg/mL MIC; μg/mL
E. coli ATTC 35218 104.17 ± 36.08 26.04 ± 9.02* 52.08 ± 18.04
P. aeruginosa ATTC 9027 166.67 ± 72.16 83.33 ± 36.08 166.67 ± 72.16Methods
Microbial culture and growth conditions
Antibacterial activity of statins was evaluated against dif-
ferent reference bacteria including E. coli ATTC 35218,
Pseudomonas aeruginosa ATTC 9027, MSSA ATTC
25213, MRSA ATTC 43300, Streptococcus pneumoniae
ATTC 25923, VSE ATTC 19433, VRE ATTC 51299, A.
baumannii ATTC 17978, P. mirabilis ATTC 12459, Kleb-
siella pneumoniae ATTC 13883, Streptococcus pyogenes
ATTC 19615, Haemophilus influenzae ATTC 29247, S.
epidermidis ATTC 12228, E. aerogenes ATTC 29751,
Citrobacter freundii ATTC 8090, E. cloacae ATTC 13047,
and against clinical isolates. Eighty clinical isolates were
used in this study, comprising 14 different bacterial spe-
cies. They were obtained from non-duplicate clinical spe-
cimens, including ear swab, throat swab, vaginal swab,
sputum, urine, and blood culture, from the Microbiology
Laboratory at King Abdullah University Hospital (KAUH)
in north of Jordan, between April and September of 2010.
The organisms were stored at −70°C in trypticase-soy
broth and 20% glycerol (BBL Microbiology Systems, Md,
USA). When ready for batch susceptibility testing, sam-
ples were thawed. To ensure purity and viability, samples
were, then, passed 3 times. Minimum inhibitory concen-
trations (MICs) were determined in accordance with the
Clinical and Laboratory Standards Institute (CLSI) [25].MSSA ATTC 25213 208.33 ± 72.16 41.67 ± 18.04* 26.04 ± 9.02*
MRSA ATTC 43300 500 ± 0.00 83.33 ± 36.08* 166.67 ± 72.16*
S. pneumoniae
ATTC 25923
333.33 ± 144.33 104.17 ± 36.08 166.67 ± 72.16
VSE ATTC 19433 333.33 ± 144.33 83.33 ± 36.08* 52.08 ± 18.04*
VRE ATTC 51299 500 ± 0.00 166.67 ± 72.16* 104.17 ± 36.08*
A. baumannii ATTC 17978 333.33 ± 144.33 15.62 ± 0.00* 104.17 ± 36.08*
P. mirabilis ATTC 12459 250 ± 0.00 62.5 ± 0.00* 166.67 ± 72.16
K. pneumoniae
ATTC 13883
333.33 ± 144.33 166.67 ± 72.16 166.67 ± 72.16
S. pyogenes ATTC 19615 166.67 ± 72.16 83.33 ± 36.08 62.5 ± 0.00
H. influenzae ATTC 29247 166.67 ± 72.16 83.33 ± 36.084 52.08 ± 18.04
S. epidermidis ATTC 12228 166.67 ± 72.16 20.83 ± 9.02* 26.04 ± 9.02*
E. aerogenes ATTC 29751 104.17 ± 36.08 15.62 ± 0.00* 26.04 ± 9.02*
C. freundii ATTC 8090 166.67 ± 72.16 83.33 ± 36.08 52.08 ± 18.04
E. cloacae ATTC 13047 166.67 ± 72.16 41.67 ± 18.04* 62.5 ± 0.00
MICs were determined using serial dilution method according to the
procedures National Committee for Clinical Laboratory Standards.
* indicates significant difference from rosuvastatin group.Determination of minimum inhibitory concentration (MIC)
The MIC was determined by serial dilution method
according to the National Committee for Clinical La-
boratory Standards [26]. Briefly, statins were serially
diluted, and added to plates containing molten BBL
Muller-Hinton Gold II agar (BBL Microbiology Sys-
tems). Thereafter, plates were slightly cooled and dried.
Then, using an a steer replicator, aliquots containing
about 5 × 104 colony forming units per drop of different
bacterial strains were placed in each plate. After an 18-
hour incubation period at 37°C, plates were read. MIC
was defined as the lowest concentration at which no
growth, a faint haze or fewer than 3 discrete colonies
were detected. Plates were read in duplicate, and the
highest MIC value was recorded. The breakpoints indi-
cated in the tables of the National Committee for CLSI
[26] were used to determine susceptibility and
resistance.Chemicals
Simvastatin atorvastatin and Rosuvastatin were a gener-
ous gift from Advanced Pharmaceutical Industries
(Amman, Jordan). Drugs (simvastatin, atorvastatin and
rosuvastatin) were dissolved in DMSO to a stock con-
centration of 1 mg/ml, and they were used for MIC de-
termination. All drugs were used as raw materials.
DMSO was used to help in dissolving the drugs used. As
DMSO is known for possessing no antibacterial activity
of its own, DMSO/no statin served as a negative control.
Statistics
Analysis was performed using GraphPad Prism software
(version 4.0, GraphPad software, LA jolle, CA). One-way
ANOVA followed by Tukey’s post-test were used to de-
termine if there was any statistically significant differ-
ence. P-values <0.05 was considered significant.
Results
The antibacterial activity of atorvastatin, simvastatin,
and rosuvastatin were investigated against 16 standard
bacterial strains. Results shown in Table 1 revealed that
statins are able to induce variable degrees of antibacter-
ial activity, where atorvastatin and simvastatin are the
most potent. MSSA, MRSA, VSE, VRE, A. baumannii, S.
epidermidis, and E. aerogenes, were more sensitive to
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tatin (P< 0-05). On the other hand, E. coli, P. mirabilis,
and E. cloacae were more sensitive to atorvastatin com-
pared to both simvastatin and rosuvastatin (P< 0.05).
We next studied the antibacterial activity of statins
against 16 clinical isolates of bacteria by measuring MIC
values. Most clinical isolates were less sensitive to statins
compared to their corresponding standard strains
(Table 2). In addition, when compared for their antibac-
terial activity atorvastatin and simvastatin were signifi-
cantly more potent compared to Rosuvastatin. For
example, P. aeruginosa, MSSA, MRSA, S. pneumonia,
VRE, A. baumannii, H. influenza, S. epidermidis, E. aero-
genes, C. freundii, and E. cloacae were more sensitive to
atorvastatin and simvastatin compared to rosuvastatin (P
< 0-05, Table2). Additionally, VSE and VRE isolates were
significantly more sensitive to atorvastatin compared to
simvastatin (P< 0-05, Table 2).
Discussion
The emergence of drug resistance with patient’s poor
compliance, drugs adverse effects and the higher cost of
therapy combinations, indicates a strong need for a ther-
apy regimens with similar or higher antibiotics beneficial
properties but with better adverse effects profiles.
Results of the current study suggest a class effect anti-
bacterial activity for statins, and indicate the superiorityTable 2 Minimum inhibitory concentrations (MIC; μg/mL)
of different statins against different clinical isolates
Clinical Isolate Rosuvastatin Atorvastatin Simvastatin
MIC; μg/mL MIC; μg/mL MIC; μg/mL
E. coli Isolates 125.00 ± 16.14 100.00 ± 33.75 112.5 ± 30.19
P. aeruginosa Isolates 291.67 ± 39.53 95.83 ± 22.09* 120.83 ± 32.27*
MSSA Isolates 341.67 ± 20.84 52.08 ± 11.04* 60.42 ± 12.76*
MRSA Isolates 500.00 ± 0.00 108.33 ± 27.36* 116.67 ± 30.19*
S. pneumoniae Isolates 416.67 ± 0.00 229.17 ± 60.38* 291.67 ± 39.53*
VSE Isolates 333.33 ± 0.00 95.83 ± 22.09* 291.67± 39.53#
VRE Isolates 500.00 ± 0.00 216.67 ± 32.27* 291.67 ± 39.53*#
A. baumannii Isolates 300.00 ± 79.05 21.87 ± 4.94* 32.29 ± 6.38*
P. mirabilis Isolates 191.67 ± 32.27 127.08 ± 25.51 158.33 ± 32.27
K. pneumoniae Isolates 258.33 ± 64.55 216.67 ± 51.03 241.67 ± 60.38
S. pyogenes Isolates 275.00 ± 72.17 133.33 ± 19.76 145.83 ± 32.27
H. influenzae Isolates 366.67 ± 0.00 104.17 ± 36.08* 145.83 ± 32.27*
S. epidermidis Isolates 233.33 ± 39.52 19.78 ± 4.94* 35.41 ± 4.94*
E. aerogenes Isolates 183.33 ± 0.00 19.78 ± 4.94* 33.33 ± 4.94*
C. freundii Isolates 333.33 ± 79.06 108.33 ± 27.36* 133.33 ± 39.58*
E. cloacae Isolates 316.67 ± 64.55 113.54 ± 27.06* 143.75 ± 36.97*
MICs were determined using serial dilution method according to the
procedures National Committee for Clinical Laboratory Standards.
* indicates significant difference from rosuvastatin group. # indicates
significant difference from atorvastatin group.of the antibacterial activity of atorvastatin and simvasta-
tin against several standard bacterial strains and clinical
isolates as compared to rosuvastatin.
Statins were demonstrated to have pharmacological
actions beyond their antihyperlipdimic properties in-
cluding immunomodulatory, antioxidative and anti-
coagulant effects. A recent study indicated a direct
antimicrobial effect of simvastatin and to a lesser extent
fluvastatin against MSSA and MRSA [27]. Another study
showed the antibacterial effect of atorvastatin and rosu-
vastatin in Gram + and Gram– bacteria [28]. Results of
the present study extend those of previous studies to in-
clude more agents of the statins family and test these
agents against a wide range of standard bacterial strains
and clinical isolates.
A very recent study has reported MIC values for sim-
vastatin against S. pneumoniae and M. catarrhalis that
are similar to the ones reported in this study [29]. These
MIC values reflect concentrations of statins that are
higher than regular concentrations detected in human
blood during statins therapy [30]. However, since mul-
tiple dose statins are known for their favorable effect on
the course of bacterial infections [18-22], it is possible
that statins undergoes accumulation at target human tis-
sues upon multiple dosing, or there could a formation of
relevant breakdown products in vivo. Alternatively, sta-
tins could aid the action of other antibacterial agent dur-
ing the treatment of infections in human through their
reported pleiotropic actions [31-33].
Statins induce their antihyperlipdimic, via inhibition of
HMG-CoA reductase. In bacterial cells, HMG-CoA re-
ductase is essential, where it is required for the biosyn-
thesis of isoprenes [34]. However, bacterial HMG-CoA
reductase is of a different structural class with an affinity
for statins that is 10 000 times weaker than the enzyme
found in eukaryotes [34]. Thus, it is unlikely that anti-
bacterial activity of statins can be attributed to the
known mechanism of action (i.e. inhibition of HMG-
CoA reductase). Other possible mechanisms could be
related to the pleiotropic properties of statins. For ex-
ample, multiple statins including atorvastatin and sim-
vastatin, were shown to be cytotoxic, to suppress cells
growth, and to promote apoptosis [31-33]. It is possible
that the currently reported antibacterial activity of sta-
tins is related to such effects.
Results of the current study showed the superiority of
the antibacterial effcets of atorvastatin or simvastatin to
that of rosuvastatin. Previous studies have reported dis-
tinct effects, other than the antibacterial activity, for
atorvastatin and simvastatin, compared to other mem-
bers of statins [35,36]. Additionally, our results show
that atrovastatin was superior to simvastatin against VSE
and VRE clinical isolates. These distinct effects could
also be related to the differences in chemical structure
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product of fungal fermentation, whereas atorvastatin is a
chemically synthesized derivative. Additionally, satins
differ in their lipids affinity, thus, they could have differ-
ent intrinsic activities. However, these points need more
study, and could be a matter of future work.
Conclusion
In summary, results of the current study raise the possi-
bility of a potentially important class effect and future
studies are recommended to elucidate mechanism (s) by
which atorvastatin and simvastatin are inducing their
antibacterial effects.
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